Drug intelligence / Profile preview

measles vaccine + mumps vaccine + rubella vaccine

Development stage
Unknown
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

The measles, mumps, and rubella (MMR) vaccine is a trivalent live attenuated biologic vaccine designed to provide active immunity against measles, mumps, and rubella. This specific formulation, containing the Moraten measles strain, the Jeryl Lynn mumps strain, and the Wistar RA 27/3 rubella strain, was evaluated in a Phase 4 clinical trial (NCT00731965) led by Dr. N.M. Wulffraat at the University Medical Centre Utrecht. The study specifically investigated the safety and immunogenicity of an MMR booster in children aged 4 to 9 years with Juvenile Idiopathic Arthritis (JIA), including those on immunosuppressive therapy such as methotrexate. The trial demonstrated that the booster vaccination did not exacerbate JIA disease activity and successfully induced protective antibody levels, confirming its safety and efficacy in this patient population.

Brand names
M-M-R IIMMR-II
Other names
MMR vaccinelive attenuated measles-mumps-rubella vaccinemeasles, mumps, and rubella virus vaccine live

Beyond the preview

Go deeper on measles vaccine + mumps vaccine + rubella vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on measles vaccine + mumps vaccine + rubella vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call